Clinical impact of body mass index on palbociclib treatment outcomes and effect on exposure.

[1]  S. Trufan,et al.  Risk factors associated with palbociclib-induced neutropenia in patients with metastatic breast cancer , 2022, Supportive Care in Cancer.

[2]  F. Puglisi,et al.  An Integrated Pharmacological Counselling Approach to Guide Decision-Making in the Treatment with CDK4/6 Inhibitors for Metastatic Breast Cancer , 2022, Frontiers in Pharmacology.

[3]  E. Solomayer,et al.  CDK4/6 Inhibitors in Advanced HR+/HER2 – Breast Cancer: A Multicenter Real-World Data Analysis , 2022, Breast Care.

[4]  M. Gnant,et al.  Impact of body mass index on treatment and outcomes in patients with early hormone receptor-positive breast cancer receiving endocrine therapy with or without palbociclib in the PALLAS trial. , 2022, Journal of Clinical Oncology.

[5]  S. van der Flier,et al.  Palbociclib dose reductions and the effect on clinical outcomes in patients with advanced breast cancer , 2021, Breast.

[6]  M. Montico,et al.  A new dried blood spot LC-MS/MS method for therapeutic drug monitoring of palbociclib, ribociclib, and letrozole in patients with cancer. , 2021, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

[7]  T. Taguchi,et al.  Predictors for development of palbociclib-induced neutropenia in breast cancer patients as determined by ordered logistic regression analysis , 2021, Scientific Reports.

[8]  P. Neven,et al.  Safety and impact of dose reductions on efficacy in the randomised MONALEESA-2, -3 and -7 trials in hormone receptor-positive, HER2-negative advanced breast cancer , 2021, British Journal of Cancer.

[9]  O. Fletcher,et al.  Evaluation of the Association of Polymorphisms With Palbociclib‐Induced Neutropenia: Pharmacogenetic Analysis of PALOMA‐2/‐3 , 2021, The oncologist.

[10]  A. Jensen,et al.  Dose modifications of ribociclib and endocrine therapy for treatment of ER+ HER2− metastatic breast cancer , 2021, Breast Cancer Research and Treatment.

[11]  M. Ratain,et al.  The Right Dose: From Phase I to Clinical Practice. , 2021, American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting.

[12]  C. Perrin,et al.  Abstract PS5-16: Impact of drug-drug interaction on palbociclib serum levels: Interest of therapeutic drug monitoring , 2021 .

[13]  R. Finn,et al.  Impact of Dose Reduction on Efficacy: Implications of Exposure-Response Analysis of Palbociclib , 2020, Targeted Oncology.

[14]  J. Beijnen,et al.  Clinical Pharmacokinetics and Pharmacodynamics of the Cyclin-Dependent Kinase 4 and 6 Inhibitors Palbociclib, Ribociclib, and Abemaciclib , 2020, Clinical Pharmacokinetics.

[15]  A. Sartore-Bianchi,et al.  CDK4/6 Inhibitors in Breast Cancer Treatment: Potential Interactions with Drug, Gene, and Pathophysiological Conditions , 2020, International journal of molecular sciences.

[16]  C. Desmedt,et al.  Clinical implications of body mass index in metastatic breast cancer patients treated with abemaciclib and endocrine therapy. , 2020, Journal of the National Cancer Institute.

[17]  H. Rugo,et al.  Hematologic adverse events following palbociclib dose reduction in patients with hormone receptor–positive/human epidermal growth factor receptor 2–negative advanced breast cancer: pooled analysis from randomized phase 2 and 3 studies , 2020, Breast Cancer Research.

[18]  F. Puglisi,et al.  Simultaneous quantification of palbociclib, ribociclib and letrozole in human plasma by a new LC-MS/MS method for clinical application , 2020, PloS one.

[19]  M. Ratain,et al.  Interventional Pharmacoeconomics-A New Discipline for a Cost-Constrained Environment. , 2019, JAMA oncology.

[20]  K. Gelmon,et al.  Palbociclib with Letrozole in Postmenopausal Women with ER+/HER2− Advanced Breast Cancer: Hematologic Safety Analysis of the Randomized PALOMA‐2 Trial , 2019, The oncologist.

[21]  H. Iwata,et al.  Palbociclib in combination with letrozole in patients with estrogen receptor–positive, human epidermal growth factor receptor 2–negative advanced breast cancer: PALOMA-2 subgroup analysis of Japanese patients , 2018, International Journal of Clinical Oncology.

[22]  J. Ledermann,et al.  Safety and dose modification for patients receiving niraparib , 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

[23]  K. Gelmon,et al.  Palbociclib and Letrozole in Advanced Breast Cancer. , 2016, The New England journal of medicine.

[24]  S. Loi,et al.  Palbociclib in Combination With Fulvestrant in Women With Hormone Receptor-Positive/HER2-Negative Advanced Metastatic Breast Cancer: Detailed Safety Analysis From a Multicenter, Randomized, Placebo-Controlled, Phase III Study (PALOMA-3). , 2016, The oncologist.

[25]  K. Flaherty,et al.  Phase I, Dose-Escalation Trial of the Oral Cyclin-Dependent Kinase 4/6 Inhibitor PD 0332991, Administered Using a 21-Day Schedule in Patients with Advanced Cancer , 2011, Clinical Cancer Research.

[26]  K. Wilner,et al.  Phase I study of PD 0332991, a cyclin-dependent kinase inhibitor, administered in 3-week cycles (Schedule 2/1) , 2011, British Journal of Cancer.

[27]  D. Dodwell,et al.  Dose intensity in cancer chemotherapy. , 1990, British Journal of Cancer.

[28]  OUP accepted manuscript , 2022, The Oncologist.